Should I buy or sell Apellis Pharmaceuticals stock right now?

14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares. View APLS analyst ratings or view top-rated stocks .

What is Apellis Pharmaceuticals' stock price target for 2024?

14 brokerages have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they expect the company's stock price to reach $69.29 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price. View analysts price targets for APLS or view top-rated stocks among Wall Street analysts .

How have APLS shares performed in 2023?

Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of the year. Since then, APLS shares have increased by 21.3% and is now trading at $62.73. View the best growth stocks for 2023 here .

When is Apellis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024. View our APLS earnings forecast .

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to analyst estimates of $99.05 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 209.10% and a negative net margin of 222.16%. The business's quarterly revenue was up 400.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.75) earnings per share.

What ETFs hold Apellis Pharmaceuticals' stock?

ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Jacob Forward ETF (JFWD) , Vanguard Russell 2000 Growth ETF (VTWG) , Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK) . Harbor Health Care ETF (MEDI) .

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com . Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV) , OPKO Health (OPK) , Fate Therapeutics (FATE) , Sorrento Therapeutics (SRNE) , Viking Therapeutics (VKTX) , Allena Pharmaceuticals (ALNA) , Amarin (AMRN) , Anavex Life Sciences (AVXL) , Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI) .

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (3.01%), FMR LLC (1.91%), Morgan Stanley (1.36%), Polar Capital Holdings Plc (0.89%), Assenagon Asset Management S.A. (0.87%) and Fiera Capital Corp (0.78%). Insiders that own company stock include A Sinclair Dunlop , Adam J Townsend , Alec Machiels , Cedric Francois , David O Watson , Federico Grossi , James George Chopas , Jeffrey Eisele , Karen Lewis , Lukas Scheibler , Mark Jeffrey Delong , Morningside Venture Investment, Nicole D Perry , Nur Nicholson , Pascal Deschatelets , Timothy Eugene Sullivan and Victoria L Brown. View institutional ownership trends .

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Does Apellis Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals. Read More

Top-Rated StocksTop-Rated Most-Upgraded StocksMost-Upgraded

Apellis Pharmaceuticals (APLS) Stock Price, News & Analysis

$62.73

-1.31 (-2.05%)

(As of 12/8/2023 08:56 PM ET)

Compare

Today's Range: $61.35
▼
$63.50
50-Day Range: $37.14
▼
$64.82
52-Week Range: $19.83
▼
$94.75

Volume: 1.64 million shs
Average Volume: 2.67 million shs
Market Capitalization: $7.43 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $69.29

Apellis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.93 Rating Score
Upside/Downside: 10.5% Upside
$69.29 Price Target
Short Interest: Bearish
13.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.27
Upright™ Environmental Score
News Sentiment: 0.95
Based on 24 Articles This Week
Insider Trading: Selling Shares
$3.04 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.65) to ($1.81) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

189th out of 942 stocks

Pharmaceutical Preparations Industry

61st out of 424 stocks

3.5

Analyst's Opinion

Consensus Rating
Apellis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $69.29, Apellis Pharmaceuticals has a forecasted upside of 10.5% from its current price of $62.73.
Amount of Analyst Coverage
Apellis Pharmaceuticals has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
13.62% of the outstanding shares of Apellis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Apellis Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Apellis Pharmaceuticals has recently decreased by 0.55%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Apellis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Apellis Pharmaceuticals does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Apellis Pharmaceuticals has received a 67.34% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for deficiency diseases", "Pegcetacoplan", and "Clinical research services for genetic diseases" products. See details.
Environmental Sustainability
The Environmental Impact score for Apellis Pharmaceuticals is -1.27.

3.3

News and Social Media Coverage

News Sentiment
Apellis Pharmaceuticals has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 24 news articles for Apellis Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 21 people have searched for APLS on MarketBeat in the last 30 days. This is a decrease of -53% compared to the previous 30 days.
MarketBeat Follows
12 people have added Apellis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,042,028.00 in company stock.
Percentage Held by Insiders
Only 7.50% of the stock of Apellis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
90.43% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Apellis Pharmaceuticals are expected to grow in the coming year, from ($4.65) to ($1.81) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Apellis Pharmaceuticals is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Apellis Pharmaceuticals is -11.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Apellis Pharmaceuticals has a P/B Ratio of 40.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Apellis Pharmaceuticals Stock (NASDAQ:APLS)

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, cold agglutinin disease, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, amyotrophic lateral sclerosis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy (GA). The company also develops APL-2006, a bispecific C3 and VEGF inhibitor for treating wet age-related macular degeneration and GA; APL-1030, a C3 inhibitor for the treatment of various neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

APLS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APLS Stock News Headlines

December 11, 2023 | americanbankingnews.com

Zacks Research Research Analysts Increase Earnings Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)

December 8, 2023 | americanbankingnews.com

Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Insider Sells $600,000.00 in Stock

December 11, 2023 | Financial Alphas (Ad)

Countries Are Investing Heavily Into Securing Energy Independence

There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.

December 7, 2023 | americanbankingnews.com

Apellis Pharmaceuticals (NASDAQ:APLS) Trading Down 2.1% Following Insider Selling

December 6, 2023 | seekingalpha.com

Apellis Pharmaceuticals: Focus Shifts Toward Market Share After Apparent Safety Resolution

December 5, 2023 | msn.com

B of A Securities Upgrades Apellis Pharmaceuticals (APLS)

December 5, 2023 | markets.businessinsider.com

Apellis Pharmaceuticals Upgraded To Buy: Analyst Sees Potential In Syfovre's Strong Launch

December 5, 2023 | markets.businessinsider.com

14 Analysts Have This to Say About Apellis Pharmaceuticals

December 11, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

December 5, 2023 | americanbankingnews.com

Apellis Pharmaceuticals (NASDAQ:APLS) Upgraded at Bank of America

December 4, 2023 | markets.businessinsider.com

Positive Outlook for Apellis Pharmaceuticals with Buy Rating and Anticipated Share Price Return

December 1, 2023 | benzinga.com

Apellis Pharmaceuticals Options Trading: A Deep Dive into Market Sentiment

December 1, 2023 | finance.yahoo.com

Apellis Pharmaceuticals, Inc. (APLS) Up 9.2% Since Last Earnings Report: Can It Continue?

November 30, 2023 | finance.yahoo.com

Vanguard Health Care Fund's Strategic Moves: Spotlight on Ono Pharmaceutical Co Ltd

November 23, 2023 | finance.yahoo.com

APLS Jan 2025 120.000 put

November 17, 2023 | benzinga.com

Apellis Pharmaceuticals's Options Frenzy: What You Need to Know

November 10, 2023 | markets.businessinsider.com

Apellis Pharmaceuticals (APLS) Buy Rating: Evaluating the Commercial Potential of Syfovre amid Retinal Vasculitis Concerns

November 10, 2023 | msn.com

Goldman Sachs Initiates Coverage of Apellis Pharmaceuticals (APLS) with Buy Recommendation

November 9, 2023 | finance.yahoo.com

Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View

November 8, 2023 | morningstar.com

Apellis Pharmaceuticals Inc APLS

November 8, 2023 | markets.businessinsider.com

Hold Rating on Apellis Pharmaceuticals Amidst Syfovre’s Success and Izervay’s Potential Competition

November 7, 2023 | markets.businessinsider.com

Hold Rating on Apellis Pharmaceuticals Amid Clinical Wins and Market Uncertainties

November 3, 2023 | markets.businessinsider.com

Buy Rating on Apellis Pharmaceuticals: Growth Potential from Syfovre Sales and European Market Expansion

November 2, 2023 | msn.com

Mizuho Initiates Coverage of Apellis Pharmaceuticals (APLS) with Neutral Recommendation

November 2, 2023 | markets.businessinsider.com

21 Analysts Have This to Say About Apellis Pharmaceuticals

November 1, 2023 | seekingalpha.com

Apellis Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

November 1, 2023 | finance.yahoo.com

Apellis Pharmaceuticals Reports Third Quarter 2023 Financial Results

See More Headlines

Receive APLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apellis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2023
Today: 12/10/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:APLS
CUSIP: N/A
CIK: 1492422
Web: www.apellis.com
Phone: (617) 977-5700
Fax: N/A
Employees: 767
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $69.29
High Stock Price Target: $93.00
Low Stock Price Target: $29.00
Potential Upside/Downside: +10.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.93
Research Coverage: 14 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.25)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-652,170,000.00
Net Margins: -222.16%
Pretax Margin: -222.37%
Return on Equity: -209.10%
Return on Assets: -69.82%

Debt

Debt-to-Equity Ratio: 0.40
Current Ratio: 4.29
Quick Ratio: 3.76

Sales & Book Value

Annual Sales: $75.42 million
Price / Sales: 98.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.54 per share
Price / Book: 40.73

Miscellaneous

Outstanding Shares: 118,500,000
Free Float: 109,613,000
Market Cap: $7.43 billion
Optionable: Not Optionable
Beta: 0.96

Social Links

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Cedric Francois M.D. (Age 51)
Ph.D., Co-Founder, President, CEO & Director
Comp: $1.2M
Dr. Pascal Deschatelets Ph.D. (Age 53)
Co-Founder & Chief Scientific Officer
Comp: $688.05k
Mr. Alec Machiels J.D. (Age 50)
MBA, Co-Founder & Director
Comp: $72.5k
Mr. Timothy E. Sullivan (Age 52)
CFO & Treasurer
Comp: $716.41k
Mr. David O. Watson Esq. (Age 50)
J.D., General Counsel
Comp: $675.35k
Mr. Adam J. Townsend (Age 46)
Chief Commercial Officer
Comp: $701.61k
Ms. Nur Nicholson (Age 54)
Chief Technical Operations Officer
Comp: $373.4k
Mr. James G. Chopas CPA (Age 57)
VP, Corporate Controller & Chief Accounting Officer
Ms. Meredith Kaya
Senior Vice President, Investor Relations & Strategic Finance
Ms. Karen Lewis (Age 51)
Chief People Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APLS Stock Analysis - Frequently Asked Questions

Should I buy or sell Apellis Pharmaceuticals stock right now?: 14 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" APLS shares.
View APLS analyst ratings or view top-rated stocks.
What is Apellis Pharmaceuticals' stock price target for 2024?: 14 brokerages have issued twelve-month target prices for Apellis Pharmaceuticals' stock. Their APLS share price targets range from $29.00 to $93.00. On average, they expect the company's stock price to reach $69.29 in the next twelve months. This suggests a possible upside of 10.5% from the stock's current price.
View analysts price targets for APLS or view top-rated stocks among Wall Street analysts.
How have APLS shares performed in 2023?: Apellis Pharmaceuticals' stock was trading at $51.71 at the beginning of the year. Since then, APLS shares have increased by 21.3% and is now trading at $62.73.
View the best growth stocks for 2023 here.
When is Apellis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 20th 2024.
View our APLS earnings forecast.
How were Apellis Pharmaceuticals' earnings last quarter?: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) released its quarterly earnings data on Wednesday, November, 1st. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($0.88) by $0.29. The firm earned $110.40 million during the quarter, compared to analyst estimates of $99.05 million. Apellis Pharmaceuticals had a negative trailing twelve-month return on equity of 209.10% and a negative net margin of 222.16%. The business's quarterly revenue was up 400.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.75) earnings per share.
What ETFs hold Apellis Pharmaceuticals' stock?: ETFs with the largest weight of Apellis Pharmaceuticals (NASDAQ:APLS) stock in their portfolio include Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Jacob Forward ETF (JFWD), Vanguard Russell 2000 Growth ETF (VTWG), Principal Healthcare Innovators ETF (BTEC) and Vanguard Small-Cap Growth ETF (VBK).Harbor Health Care ETF (MEDI).

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?: 18 employees have rated Apellis Pharmaceuticals Chief Executive Officer Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among the company's employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 74.0% of employees surveyed would recommend working at Apellis Pharmaceuticals to a friend.
What other stocks do shareholders of Apellis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).
When did Apellis Pharmaceuticals IPO?: (APLS) raised $150 million in an IPO on Thursday, November 9th 2017. The company issued 10,700,000 shares at a price of $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.
Who are Apellis Pharmaceuticals' major shareholders?: Apellis Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Jennison Associates LLC (3.01%), FMR LLC (1.91%), Morgan Stanley (1.36%), Polar Capital Holdings Plc (0.89%), Assenagon Asset Management S.A. (0.87%) and Fiera Capital Corp (0.78%). Insiders that own company stock include A Sinclair Dunlop, Adam J Townsend, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, James George Chopas, Jeffrey Eisele, Karen Lewis, Lukas Scheibler, Mark Jeffrey Delong, Morningside Venture Investment, Nicole D Perry, Nur Nicholson, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends.
How do I buy shares of Apellis Pharmaceuticals?: Shares of APLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
Does Apellis Pharmaceuticals have any subsidiaries?: The following companies are subsidiares of Apellis Pharmaceuticals: APL DEL Holdings II LLC, APL DEL Holdings LLC, APL PRG I Corp., APL Sales I LLC, Apellis Australia Pty Ltd., Apellis Bermuda Ltd., Apellis Cayman Holdings Limited, Apellis France S.A.S., Apellis Germany GmbH, Apellis Ireland Ltd., Apellis MA Securities Inc., Apellis Netherlands B.V., Apellis Switzerland GmbH, Apellis U.K. Limited, and Potentia Pharmaceuticals.
Read More

This page (NASDAQ:APLS) was last updated on 12/11/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial